A P DeFilippis1, S N Rai2, A Cambon3, R J Miles4, A S Jaffe5, A B Moser6, R O Jones6, R Bolli7, S P Schulman8. 1. University of Louisville, Rudd Heart & Lung Center/Kentucky One Health, Louisville, KY, USA; The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. Electronic address: apdefi01@louisville.edu. 2. Biostatistics Shared Facility, JG Brown Cancer Center, University of Louisville, Louisville, KY, USA. 3. Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA. 4. University of Louisville School of Medicine, Louisville, KY, USA. 5. Cardiovascular division, Mayo Clinic, Rochester, MN, USA. 6. The Hugo W. Moser Research Institute, The Kennedy Krieger Institute, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, USA. 8. Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND AND AIMS: Omega-3 fatty acids suppress Thromboxane A(2) (TxA(2)) generation via mechanisms independent to that of aspirin therapy. We sought to evaluate whether baseline omega-3 fatty acid levels influence arachidonic acid proven platelet-cyclooxygenase-1 (COX-1) independent TxA(2) generation (TxA(2) generation despite adequate aspirin use). METHODS AND RESULTS: Subjects with acute myocardial infarction, stable CVD or at high risk for CVD, on adequate aspirin therapy were included in this study. Adequate aspirin action was defined as complete inhibition of platelet-COX-1 activity as assessed by <10% change in light transmission aggregometry to ≥1 mmol/L arachidonic acid. TxA(2) production was measured via liquid chromatography-tandem mass spectrometry for the stable TxA(2) metabolite 11-dehydro-thromboxane B2 (UTxB2) in urine. The relationship between baseline fatty acids, demographics and UTxB(2) were evaluated. Baseline omega-3 fatty acid levels were not associated with UTxB(2) concentration. However, smoking was associated with UTxB(2) in this study. CONCLUSION: Baseline omega-3 fatty acid levels do not influence TxA(2) generation in patients with or at high risk for CVD receiving adequate aspirin therapy. The association of smoking and TxA(2) generation, in the absence of platelet COX-1 activity, among aspirin treated patients warrants further study.
BACKGROUND AND AIMS: Omega-3 fatty acids suppress Thromboxane A(2) (TxA(2)) generation via mechanisms independent to that of aspirin therapy. We sought to evaluate whether baseline omega-3 fatty acid levels influence arachidonic acid proven platelet-cyclooxygenase-1 (COX-1) independent TxA(2) generation (TxA(2) generation despite adequate aspirin use). METHODS AND RESULTS: Subjects with acute myocardial infarction, stable CVD or at high risk for CVD, on adequate aspirin therapy were included in this study. Adequate aspirin action was defined as complete inhibition of platelet-COX-1 activity as assessed by <10% change in light transmission aggregometry to ≥1 mmol/L arachidonic acid. TxA(2) production was measured via liquid chromatography-tandem mass spectrometry for the stable TxA(2) metabolite 11-dehydro-thromboxane B2 (UTxB2) in urine. The relationship between baseline fatty acids, demographics and UTxB(2) were evaluated. Baseline omega-3 fatty acid levels were not associated with UTxB(2) concentration. However, smoking was associated with UTxB(2) in this study. CONCLUSION: Baseline omega-3 fatty acid levels do not influence TxA(2) generation in patients with or at high risk for CVD receiving adequate aspirin therapy. The association of smoking and TxA(2) generation, in the absence of platelet COX-1 activity, among aspirin treated patients warrants further study.
Authors: John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Christine M Albert; Hannia Campos; Meir J Stampfer; Paul M Ridker; JoAnn E Manson; Walter C Willett; Jing Ma Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Angela van der Plas; Sandrine Pouly; Guillaume de La Bourdonnaye; Wee Teck Ng; Gizelle Baker; Frank Lüdicke Journal: Toxicol Rep Date: 2018-04-19
Authors: Annalisa Noce; Giulia Marrone; Francesca Di Daniele; Manuela Di Lauro; Anna Pietroboni Zaitseva; Georgia Wilson Jones; Antonino De Lorenzo; Nicola Di Daniele Journal: Nutrients Date: 2020-08-20 Impact factor: 5.717